197 related articles for article (PubMed ID: 26482553)
1. Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.
Roth JA; Ramsey SD; Carlson JJ
Oncologist; 2015 Dec; 20(12):1355-64. PubMed ID: 26482553
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
[TBL] [Abstract][Full Text] [Related]
3. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
Govers TM; Caba L; Resnick MJ
J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
Govers TM; Hessels D; Vlaeminck-Guillem V; Schmitz-Dräger BJ; Stief CG; Martinez-Ballesteros C; Ferro M; Borque-Fernando A; Rubio-Briones J; Sedelaar JPM; van Criekinge W; Schalken JA
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):101-109. PubMed ID: 30127462
[TBL] [Abstract][Full Text] [Related]
6. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
Dijkstra S; Govers TM; Hendriks RJ; Schalken JA; Van Criekinge W; Van Neste L; Grutters JPC; Sedelaar JPM; van Oort IM
BJU Int; 2017 Nov; 120(5):659-665. PubMed ID: 28370948
[TBL] [Abstract][Full Text] [Related]
8. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.
Sathianathen NJ; Kuntz KM; Alarid-Escudero F; Lawrentschuk NL; Bolton DM; Murphy DG; Weight CJ; Konety BR
J Urol; 2018 Dec; 200(6):1215-1220. PubMed ID: 29906434
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
[TBL] [Abstract][Full Text] [Related]
10. A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
Reed SD; Stewart SB; Scales CD; Moul JW
Value Health; 2014 Jul; 17(5):545-54. PubMed ID: 25128047
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
Lu L; Peters J; Roome C; Stein K
BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
[TBL] [Abstract][Full Text] [Related]
12. A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer.
White C; Nimeh T; Gazelle GS; Weinstein MC; Loughlin KR
Cancer; 2019 Mar; 125(6):952-962. PubMed ID: 30561761
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer.
Lobo JM; Trifiletti DM; Sturz VN; Dicker AP; Buerki C; Davicioni E; Cooperberg MR; Karnes RJ; Jenkins RB; Den RB; Showalter TN
Clin Genitourin Cancer; 2017 Jun; 15(3):e299-e309. PubMed ID: 28089723
[TBL] [Abstract][Full Text] [Related]
14. Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer.
Boyd KA; Jones RJ; Paul J; Birrell F; Briggs AH; Leung HY
BMJ Open; 2015 Oct; 5(10):e007925. PubMed ID: 26482768
[TBL] [Abstract][Full Text] [Related]
15. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
[TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer.
Chang EM; Punglia RS; Steinberg ML; Raldow AC
Urology; 2019 Apr; 126():89-95. PubMed ID: 30580007
[TBL] [Abstract][Full Text] [Related]
17. A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer.
Lyth J; Andersson SO; Andrén O; Johansson JE; Carlsson P; Shahsavar N
Scand J Urol Nephrol; 2012 Feb; 46(1):19-25. PubMed ID: 21905981
[TBL] [Abstract][Full Text] [Related]
18. Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
Sanyal C; Aprikian AG; Cury FL; Chevalier S; Dragomir A
Cancer; 2016 Apr; 122(7):1085-96. PubMed ID: 26828716
[TBL] [Abstract][Full Text] [Related]
19. [Health-economic evaluation of magnetic resonance imaging before biopsy for diagnosis of prostate cancer].
Stadlbauer A; Bernt R; Salomonowitz E; Plas E; Strunk G; Eberhardt K
Rofo; 2011 Oct; 183(10):925-32. PubMed ID: 21863536
[TBL] [Abstract][Full Text] [Related]
20. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
